FDA OKs DexCom's continuous glucose technology
This article was originally published in Clinica
DexCom saw its shares jump last week, after the US FDA approved for sale its continuous glucose monitor for helping diabetics more conveniently and effectively manage their blood sugar levels.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.